Ex-CJI Ranjan Gogoi takes oath as Rajya Sabha MP

Panaji, Mar 26: Three persons, all with travel history abroad, tested positive for coronavirus in Goa on Wednesday, health department officials said, as the tourist haven joined the states which have reported COVID-19 cases.

This is the first time the tourist state has reported coronavirus positive cases.

The Directorate of Health Services, in a late night press statement here, said three suspected cases of COVID-19 from Goa, whose test results were awaited, have turned out positive.

All three are male patients of ages 25, 29 and 55 years. They have travel history of returning to Goa from Spain, Australia and the USA, respectively, the officials said.

The condition of the trio, admitted in Goa Medical College and Hospital near here, is stable, the officials added.

Chief Minister Pramod Sawant said the state is providing the best healthcare facility to the diagnosed patients.

I have been informed by the state Directorate of Health services that three individuals have been tested positive for #COVID19 in Goa.

"We are providing the best healthcare facility to the diagnosed patients, he said.

Their condition is stable at present. e have also traced their contacts and are quarantining them, Sawant added.

Health Minister Vishwajit Rane said the government is taking all precautions and following guidelines related to the viral infection.

In view of the three positive coronavirus cases in Goa, we are following all guidelines laid down by the central government and taking all precautions with the support of chief minister Pramod Sawant, he said.

Our testing facility will be up and running in the next two days. Our team of doctors is doing its est to make sure we contain the spread of virus in the state, Rane added.

New Delhi, Jun 25: After the Drug Controller General of India (DCGI) given its approval to manufacture and market the generic version of COVID-19 drug Remdesivir, COVIFOR, Hyderabad-based drugmaker Hetero Limited has delivered the first set of 20,000 vials in two equal lots of 10,000 each across 5 states.

The first batch, which is being marketed under the brand name of COVIFOR, was delivered to Maharashtra, Delhi, Gujarat Tamil Nadu and Hyderabad. Hetero has set a target to produce one lakh vials of the drug in two-three weeks.

The other lot would be supplied to Kolkata, Indore, Bhopal, Lucknow, Patna, Bhubaneshwar, Ranchi, Vijayawada, Cochin, Trivandrum and Goa within a week to meet the emergency requirements.

Managing director of Hetero Healthcare M Srinivasa Reddy said “the launch of Covifor in the country is a milestone in addressing public health emergencies. Through Covifor, we hope to reduce the treatment time of a patient in a hospital thereby reducing the increasing pressure on the medical infrastructure overburdened ue to accelerating COVID-19 infection rates," he said as reported by news agency.

"We are closely working with the government and the medical community to make Covifor quickly accessible to both public and private healthcare settings across the country”, Reddy said.

Covifor is a generic brand of Remdesivir which is used for the treatment of COVID-19 in adults and children hospitalised with strong symptoms of the disease. The Health Ministry had, on June 13, recommended the use of anti-viral drug Remdesivir in moderate stage of COVID-19.

Dr Reddys Laboratories and Hetero are among others which have separately entered into non-exclusive licensing agreements with the original drug-maker Gilead Sciences Inc to register, make and sell the investigational drug Remdesivir in India and other countries.

Remdesivir would be made in the company's formulation facility in Hyderabad, which has been approved by global regulatory authorities such as US Food and Drug Administration (USFDA) and EU, among others, Hetero had earlier said.

The treatment first showed improvement in trials on coronavirus patients and was approved for emergency use in severely ill patients in the United States and South Korea.